Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy(PANTHEON) | terminated | Phase 2 | 67 | AIO-Studien-gGmbHOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04653389 | Perioperative Therapy for Hepatocellular Carcinoma | terminated | Phase 2 | 10 | Zhejiang UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04476329 | Optimization for Regorafenib in HCC(ReDos HCC) | terminated | Phase 2 | 7 | SC Liver Research Consortium, LLCOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT03050814 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | terminated | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02137252 | Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT02934503 | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 5 | NYU Langone HealthOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | terminated | Phase 2 | 29 | BerGenBio ASAINDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma(GCC 1314) | terminated | Phase 2 | 3 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT02387216 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC(SHERLOC) | terminated | Phase 2 | 153 | Elevation OncologyINDUSTRY | 6 | Oct 12, 2021 | clinicaltrials |
| NCT02404506 | Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer | terminated | Phase 2 | 78 | Swiss Cancer InstituteOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT03894007 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer(PREDIXIIHER2) | terminated | Phase 2 | 6 | Renske AltenaOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02959554 | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control(NIVOSWITCH) | terminated | Phase 2 | 49 | AIO-Studien-gGmbHOTHER | 2 | Sep 8, 2021 | clinicaltrials |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 23 | SanofiINDUSTRY | 5 | Sep 8, 2021 | clinicaltrials |
| NCT03186937 | A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer | terminated | Phase 2 | 6 | University of Wisconsin, MadisonOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT01649180 | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma(PrE0801) | terminated | Phase 2 | 3 | PrECOG, LLC.OTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03988647 | Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | terminated | Phase 2 | 1 | Stanford UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | terminated | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT01784861 | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors | terminated | Phase 1 / Phase 2 | 23 | Washington University School of MedicineOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT03190213 | Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma(Pembro NEC) | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT03670030 | A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System | terminated | Phase 2 | 5 | Robert RamirezOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT01147536 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence | terminated | Phase 2 | 12 | Agenus Inc.INDUSTRY | 2 | Jun 3, 2021 | clinicaltrials |
| NCT01032850 | Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | terminated | Phase 2 | 15 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT03875859 | Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC) | terminated | Phase 2 | 4 | Kavita SarinOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT00003487 | Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus | terminated | Phase 2 | 8 | Burzynski Research InstituteOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT02621333 | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma | terminated | Phase 2 | 280 | Henan Cancer HospitalOTHER_GOV | 1 | May 12, 2021 | clinicaltrials |
| NCT03608878 | Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype | terminated | Phase 2 | 5 | Chang Gung Memorial HospitalOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT01253668 | Brivanib Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT02722369 | STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 72 | University College, LondonOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Medstar Health Research InstituteOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00324740 | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer | terminated | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT03303469 | Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging | terminated | Phase 2 | 3 | University of Alabama at BirminghamOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 17, 2021 | clinicaltrials |
| NCT00285415 | A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation | terminated | Phase 2 | 46 | Carilion ClinicOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03008512 | A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib | terminated | Phase 2 | 5 | Gachon University Gil Medical CenterOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02524119 | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma(LEE001) | terminated | Phase 2 | 5 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03244358 | Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer | terminated | Phase 2 | 12 | Sun Yat-sen UniversityOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT02495103 | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 2 | University of California, DavisOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03219372 | Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence | terminated | Phase 2 | 1 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02853162 | Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)(ARREST) | terminated | Phase 2 | 30 | UMC UtrechtOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 30, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 11, 2022source: clinicaltrials